Plasma Heat Shock Protein 90 Alpha: A Valuable Predictor of Early Chemotherapy Effectiveness in Advanced Non-Small-Cell Lung Cancer
- 9 November 2020
- journal article
- research article
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 27, e924778-1-e924778-6
- https://doi.org/10.12659/msm.924778
Abstract
Plasma Heat Shock Protein 90 Alpha: A Valuable Predictor of Early Chemotherapy Effectiveness in Advanced Non-Small-Cell Lung Cancer - Article abstract #924778This publication has 27 references indexed in Scilit:
- Discovery of 2′,4′-dimethoxychalcone as a Hsp90 inhibitor and its effect on iressa-resistant non-small cell lung cancer (NSCLC)Archives of Pharmacal Research, 2015
- Biological relevance of Hsp90‐binding immunophilins in cancer development and treatmentInternational Journal of Cancer, 2015
- Plasma Levels of Heat Shock Protein 90 Alpha Associated with Lung Cancer Development and Treatment ResponsesClinical Cancer Research, 2014
- Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myelomaLeukemia, 2014
- The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancerTargeted Oncology, 2014
- PLCγ1–PKCγ Signaling‐Mediated Hsp90α Plasma Membrane Translocation Facilitates Tumor MetastasisTraffic, 2014
- Hsp90α forms a stable complex at cilia neck for signal molecules interaction in cilia-mediated IGF-1 receptor signalingJournal of Cell Science, 2014
- Reviews Palliative care in patients with lung cancerContemporary Oncology, 2013
- The Regulatory Mechanism of Extracellular Hsp90α on Matrix Metalloproteinase-2 Processing and Tumor AngiogenesisOnline Journal of Public Health Informatics, 2010
- The regulatory mechanism of Hsp90α secretion and its function in tumor malignancyProceedings of the National Academy of Sciences of the United States of America, 2009